Zhaoke Ophthalmology (HKG:6622) shrank its attributable loss for the year 2024 to 237.5 million yuan from 385 million yuan in the year-ago period, a Monday filing with the Hong Kong bourse said.
Loss per share stood at 0.43 yuan, down from 0.71 yuan in the corresponding period last year.
The ophthalmic pharmaceutical company's revenue for the year increased to 69.3 million yuan from 18.8 million yuan a year prior, mainly due to a rise in licensing income.
The firm attributed the lower loss mainly to a milestone payment received under a product license agreement, significant sales growth in key ophthalmic drug products, and lower R&D expenses.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。